New FDA clearances expand Hamamatsu’s FDA-cleared NanoZoomer portfolio with compact benchtop and high-throughput digital pathology solutions.
Beginning October 1, 2026, hospitals using Bayesian’s continuous sepsis monitor can receive additional Medicare reimbursement for eligible inpatient cases, the first reimbursement pathway of its kind for presuspicion sepsis monitoring.
CPETWise automates and standardises CPET workflow, transforming complex physiological data into streamlined processes.
The autonomous triage system’s European market authorisation comes as AI becomes increasingly embedded into the cancer screening paradigm.
Stryker (NYSE: SYK) has announced the first clinical use of SportsSuite Vision using the mixed-reality Apple Vision Pro.